Company intelligence / Profile preview

MediSieve

London, England, United Kingdommedisieve.com ↗

Ownership: Private
Development stage: Phase 1

Overview

MediSieve has developed a novel magnetic blood filtration system using nanoengineered magnetic beads to selectively remove specific disease-causing substances from the bloodstream. This approach aims for high selectivity and efficacy compared to traditional filtration methods. The technology has shown promise in preclinical studies for conditions such as severe malaria, hyperinflammation, and potentially enabling gene therapies by clearing inhibitory antibodies. No published results from large-scale clinical trials are available yet.

Therapeutic areas: HematologyImmunologyInfectious Diseases
Modalities: DeviceNanoparticle (nanoengineered magnetic particles)Platform therapy (Magnetic Haemofiltration/Blood Filtration)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on MediSieve.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MediSieve.

Explore the full profile